Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?
Open Access
- 2 May 2019
- journal article
- research article
- Published by Springer Nature in Current Hepatology Reports
- Vol. 18 (2) , 174-186
Abstract
No abstract availableKeywords
Funding Information
- Medical University of Vienna
This publication has 84 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosisJournal of Gastroenterology, 2011
- Comparison of balloon vs. straight catheter for the measurement of portal hypertensionAlimentary Pharmacology & Therapeutics, 2010
- β‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysisLiver International, 2009
- Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient‐guided pharmacological therapyAlimentary Pharmacology & Therapeutics, 2009
- Nonselective β-Blockers and Hepatic Venous Pressure Gradient Monitoring: What Lies Behind NonresponseGastroenterology, 2008
- How to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β BlockersGastroenterology, 2007
- Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosisJournal of Hepatology, 2004
- “A la carte” treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleedingHepatology, 2002
- Low–Dose Midazolam Sedation: An Option for Patients Undergoing Serial Hepatic Venous Pressure MeasurementsHepatology, 1999